US 12,258,350 B1
Crystalline forms of 4-ethoxy-n-(2-methoxyethyl)-n-methyl-3-(5-methyl-4-oxo-7-propyl-3,4-dihydroimidazo[5, 1-f][1,2,4]triazin-2-yl)benzenesulfonamide
Bridget McCarthy Cole, Quincy, MA (US); Enoch Kim, Marblehead, MA (US); Dhanapalan Nagarathnam, Marblehead, MA (US); and Paul Sweetnam, Marblehead, MA (US)
Assigned to Retension Pharmaceuticals, Inc., Falls Church, VA (US)
Filed by Retension Pharmaceuticals, Inc., Falls Church, VA (US)
Filed on Nov. 14, 2024, as Appl. No. 18/948,031.
Int. Cl. A61K 31/53 (2006.01); C07D 253/10 (2006.01); C07D 487/04 (2006.01)
CPC C07D 487/04 (2013.01) [A61K 31/53 (2013.01)] 15 Claims
 
1. A crystalline form of Compound I:

OG Complex Work Unit Chemistry
wherein the crystalline form is characterized by a powder X-ray diffraction (PXRD) diffractogram comprising characteristic peaks (° 2θ) at angles of 11.7626° ±0.2° 2θ, 14.0190° ±0.2° 2θ, 20.0045° ±0.2° 2θ, and 24.8947° ±0.2° 2θ.
 
6. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the crystalline form of claim 1.